A detailed history of Royal Bank Of Canada transactions in Caribou Biosciences, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 38,685 shares of CRBU stock, worth $78,143. This represents 0.0% of its overall portfolio holdings.

Number of Shares
38,685
Previous 42,809 9.63%
Holding current value
$78,143
Previous $70,000 7.14%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.56 - $2.73 $6,433 - $11,258
-4,124 Reduced 9.63%
38,685 $75,000
Q2 2024

Aug 14, 2024

BUY
$1.62 - $5.05 $6,564 - $20,462
4,052 Added 10.45%
42,809 $70,000
Q1 2024

Nov 05, 2024

SELL
$4.82 - $8.26 $19,530 - $33,469
-4,052 Reduced 9.47%
38,757 $199,000
Q1 2024

May 15, 2024

SELL
$4.82 - $8.26 $1.17 Million - $2.01 Million
-243,180 Reduced 86.25%
38,757 $199,000
Q4 2023

Feb 14, 2024

BUY
$3.58 - $6.25 $894,989 - $1.56 Million
249,997 Added 782.71%
281,937 $1.62 Million
Q3 2023

Nov 14, 2023

BUY
$4.08 - $8.14 $97,242 - $194,008
23,834 Added 294.03%
31,940 $152,000
Q2 2023

Aug 14, 2023

BUY
$4.04 - $5.47 $11,251 - $15,233
2,785 Added 52.34%
8,106 $34,000
Q1 2023

May 15, 2023

SELL
$4.3 - $7.78 $13,704 - $24,794
-3,187 Reduced 37.46%
5,321 $28,000
Q4 2022

Feb 14, 2023

BUY
$5.57 - $11.01 $31,498 - $62,261
5,655 Added 198.21%
8,508 $53,000
Q3 2022

Nov 14, 2022

BUY
$5.34 - $12.79 $2,023 - $4,847
379 Added 15.32%
2,853 $30,000
Q2 2022

Aug 15, 2022

SELL
$5.1 - $9.74 $11,475 - $21,915
-2,250 Reduced 47.63%
2,474 $14,000
Q1 2022

May 16, 2022

BUY
$8.42 - $15.32 $8,133 - $14,799
966 Added 25.71%
4,724 $44,000
Q4 2021

Feb 14, 2022

BUY
$14.59 - $23.26 $14,590 - $23,260
1,000 Added 36.26%
3,758 $58,000
Q3 2021

Nov 15, 2021

BUY
$15.75 - $30.29 $43,438 - $83,539
2,758 New
2,758 $66,000

Others Institutions Holding CRBU

About Caribou Biosciences, Inc.


  • Ticker CRBU
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,840,800
  • Market Cap $123M
  • Description
  • Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...
More about CRBU
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.